Gastrointestinal (GI): NSAIDs that block COX-1 action have correlations with GI issues as a result of inhibition in the synthesis of gastroprotective brokers including PGE2 and also other prostaglandins. This inhibition results in lowered mucin production by gastric epithelial cells, significantly less bicarbonate secretion, and less epithelial mob